In addition to bringing on impressive healthcare technology leaders in 2017, the company also made meaningful additions to its client roster, raised funds, and moved its headquarters
BOSTON--(BUSINESS WIRE)-- ZappRx, a digital health company that reduces the administrative burden associated with prescribing specialty medications, is pleased to announce the appointment of two new executive team members – James Cornicelli, vice president of corporate strategy, and Rich Kramer, vice president of commercial operations – to help the company maintain its momentum after a successful Series B round of funding. The appointments of Cornicelli and Kramer came soon after that of Libby Curtis Webb, the new senior vice president of product. The additions to leadership are in response to the company’s momentum over the last year and in anticipation of strategic growth in 2018.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171128006126/en/
Listed from left to right: James Cornicelli, Rich Kramer, Libby Curtis Webb (Photo: Business Wire)
Mr. Cornicelli will lead the development and implementation of the company’s biopharmaceutical partnership strategy and will build out a business development team to support the increasing demand to partner with ZappRx. Before joining ZappRx, Cornicelli served as Global Head of Business Development for Belgium-based UCB Biopharma’s Immunology and Bone business units. Prior to UCB, Cornicelli spent 13 years at Salix Pharmaceuticals, which was ultimately acquired for $15 billion under his guidance.
Mr. Kramer will lead ZappRx’s provider account management team as it continues expanding ZappRx’s platform into physician practices, health systems, and clinics across the United States. Kramer brings extensive expertise to his new role at ZappRx. Most recently, he served as vice president of sales at Upfront Healthcare, an early-stage healthcare technology startup, where he led commercialization.
Mrs. Webb is responsible for the strategic vision and execution of ZappRx’s product and technology operations. Webb oversees teams across all aspects of product – from product management and development to marketing. She plays an instrumental role in managing strategic relationships with partners and customers. Before joining ZappRx, Webb held leadership positions with Copatient, a medical billing advocacy company and health technology giant athenahealth.
The addition of three strong members to ZappRx’s leadership team is indicative of the company’s rapid growth and its potential for future success. Just this year, the company added three keystone customers to its roster, increased product offerings and moved into its new expanded office space in Boston, Mass. The company also announced a Series B round of funding in April 2017, bringing its total funding to over $41.5 million.
“The success and growth we’ve experienced over the last year are a testament to the challenges facing everyone involved with specialty pharmaceuticals. From the doctors to the pharmacists, and most importantly the patients, there is a lot of work to be done to get medications to the people who need them the most,” said Zoë Barry, chief executive officer and founder at ZappRx. “ZappRx is committed to this work and we’ve made great strides in 2017. We’re off to an incredible start and have already seen real, tangible results from our current customers’ and their patients but we’re only scratching the surface. Armed with new leadership, new technology, deep passion and commitment, 2018 is going to be a spectacular year for ZappRx and those we are devoted to helping!”
Half-way through the year, ZappRx announced adoption at its first three academic medical centers and large clinical sites, including Tufts Medical Center, Arizona Pulmonary Specialists, and Harbor-UCLA. ZappRx plans to continue to launch its platform across the nation within health systems and community practices with physicians who prescribe specialty medications for patients with complex pulmonary conditions.
Pulmonary Hypertension Awareness Month, recognized through November, aims to raise awareness for the disease. ZappRx’s platform is currently live in three keystone disease areas: Pulmonary Arterial Hypertension (PAH), Idiopathic Pulmonary Fibrosis (IPF), and Cystic Fibrosis (CF). ZappRx is currently expanding into other areas including neurology, oncology, rheumatology, and gastroenterology.
To learn more about ZappRx and the work it is doing to improve care for patients in need, visit them online at www.zapprx.com.
ZappRx simplifies the complex process required to order specialty medications, making it easier to collect and save all of the information required to order a prescription — including pharmacy information, payer/prior authorization requirements, and relevant patient clinical history. ZappRx then enables providers, pharmacists, and payers to digitally interact with one another to fill a prescription, reducing the need for fax and phone call interactions. The platform is currently live in three disease areas, including Pulmonary Arterial Hypertension (PAH), Idiopathic Pulmonary Fibrosis (IPF), and Cystic Fibrosis, with plans to expand to support prescribing for other areas, including neurology, oncology, rheumatology, and gastroenterology conditions.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171128006126/en/